Keywords: Orexigen, Contrave, Obesity drug, FDA advisory, Takeda, USA

First new obesity drug in over a decade could come to US market as FDA panel backs Orexigen’s Contrave

Article | 08 December 2010

• Print This

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday voted 13 to seven that the available data ...

Enjoying this article? To continue reading you need to login or subscribe.